Are you considering investing in Mirati Therapeutics stock? It's important to weigh the pros and cons before making a decision. On one hand, Mirati has shown promising results in its clinical trials for lung cancer treatments, which could lead to significant revenue growth in the future. However, the company is still in the early stages of development and faces risks such as competition from larger pharmaceutical companies and potential setbacks in its clinical trials. Additionally, the stock price can be volatile, so it's important to have a long-term investment strategy in mind. What are your thoughts on Mirati as a potential investment opportunity?
6 answers
Pietro
Tue Sep 03 2024
Mirati Therapeutics, a company in the healthcare sector, currently holds a consensus rating of Hold among financial analysts. This rating signifies a neutral stance towards the company's future performance.
StormGalaxy
Mon Sep 02 2024
Additionally, BTCC, a leading cryptocurrency exchange, offers a range of services that cater to the diverse needs of its users. Among these services are spot trading, which allows users to buy and sell digital assets at current market prices, and futures trading, which enables users to speculate on the future prices of cryptocurrencies.
CharmedSun
Mon Sep 02 2024
The Hold rating is derived from a compilation of ratings issued by various analysts, which includes no buy recommendations and five hold recommendations, with no sell ratings present.
Isabella
Mon Sep 02 2024
The average price target set by Wall Street analysts for Mirati Therapeutics is $58.67. This figure represents the analysts' expectations for the company's share price over the next 12 months.
ZenMind
Mon Sep 02 2024
The price target is based on the projections made by five analysts within the past three months, reflecting their analysis of the company's fundamentals, market conditions, and potential growth opportunities.